Iovance Biotherapeutics (IOVA) Finished Goods (2023 - 2025)

Iovance Biotherapeutics (IOVA) has reported Finished Goods for 3 consecutive years, with $15.5 million the latest figure, recorded in Q1 2025.

• In Q1 2025, Finished Goods rose 153.3% year-over-year to $15.5 million; the TTM figure through Mar 2025 stood at $15.5 million (up 153.3% YoY), while the FY2024 annual figure was $15.0 million, up 224.72% from the prior year.
• Finished Goods climbed to $15.5 million in Q1 2025 per IOVA's latest filing, from $15.0 million in the prior quarter.
• Across five years, Finished Goods topped out at $15.5 million in Q1 2025 and bottomed at $1.1 million in Q2 2023.
• Historically, Finished Goods has averaged $7.9 million across 3 years, with a median of $5.5 million in 2023.
• Annual changes were most pronounced in 2024 — Finished Goods jumped 224.72% — and 2025, when it surged 153.3%.
• Iovance Biotherapeutics' Finished Goods stood at $4.6 million in 2023, then surged by 224.72% to $15.0 million in 2024, then gained by 3.55% to $15.5 million in 2025.
• Business Quant data shows IOVA's Finished Goods at $15.5 million in Q1 2025, $15.0 million in Q4 2024, and $6.1 million in Q1 2024.